RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Depression in bipolarity (EDIT-ANDRE)

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

This appears to be a medication / drug study involving Vortioxetine, Bupropion extended release, Cariprazine (Augmentation Phase). Phase 4 studies usually happen after treatment approval, to monitor real-world use.

This study may concern people with bipolarity; age range: From 18 Years to 65 Years. The criteria appear strict, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by Mayo Clinic, which appears to be a hospital or academic medical center. The listed contact or investigator is Mayo Clinic, affiliated with Mayo Clinic. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.